BGS649 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pelvic Pain Associated With Refractory Endometriosis
Conditions
Pelvic Pain Associated With Refractory Endometriosis
Trial Timeline
Apr 15, 2010 → Mar 21, 2012
NCT ID
NCT01116440About BGS649 + Placebo
BGS649 + Placebo is a phase 2 stage product being developed by Novartis for Pelvic Pain Associated With Refractory Endometriosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01116440. Target conditions include Pelvic Pain Associated With Refractory Endometriosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01116440 | Phase 2 | Terminated |
Competing Products
11 competing products in Pelvic Pain Associated With Refractory Endometriosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Solifenacin + Placebo | Astellas Pharma | Approved | 85 |
| Tanezumab + Placebo | Pfizer | Phase 2 | 51 |
| Azithromycin | Pfizer | Phase 3 | 76 |
| Vaginal estrogen + Placebo | Pfizer | Pre-clinical | 22 |
| Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet | Pfizer | Phase 2 | 51 |
| Conjugated Estrogens Cream + Placebo Cream | Pfizer | Approved | 84 |
| BAY1834845 + Placebo | Bayer | Phase 1 | 30 |
| Ofloxacin + Avelox (Moxifloxacin, BAY12-8039) | Bayer | Phase 3 | 74 |
| Moxifloxacin (Avelox, BAY12-8039) + Levofloxacin & Metronidazole | Bayer | Phase 3 | 74 |
| Dienogest (BAY86-5258, Visanne) | Bayer | Pre-clinical | 20 |
| Sevoflurane + propofol + remifentanil | Baxter | Approved | 82 |